Neuroendocrine tumors of the gastrointestinal tract: Recent advances in molecular genetics, diagnosis, and treatment

Current Opinion in Oncology

Volumn 17, Issue 4, 2005, Pages 386-391

  Öberg, Kjell ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Imaging; Molecular genetics; Treatment; Tumor markers

Indexed keywords

5 HYDROXYTRYPTOPHAN; ALPHA INTERFERON; BORTEZOMIB; CHROMOGRANIN; DOXORUBICIN; FLUOROURACIL; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; HOMEODOMAIN PROTEIN; OCTREOTIDE; PASIREOTIDE; PENTETIC ACID; PROTEIN P55; SOMATOSTATIN; STREPTOZOCIN; STREPTOZOCIN PLUS 5 FLUOROURACIL; STREPTOZOTOCIN PLUS DOXORUBICIN; TRANSCRIPTION FACTOR CDX2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTIFICIAL EMBOLISM; CARCINOID; CHEMOEMBOLIZATION; FIBROSIS; GASTROINTESTINAL TRACT SCINTISCANNING; GASTROINTESTINAL TUMOR; HUMAN; INTERMETHOD COMPARISON; MOLECULAR GENETICS; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS;

GASTROINTESTINAL NEOPLASMS; HUMANS; MOLECULAR BIOLOGY; NEUROENDOCRINE TUMORS;

EID: 21344464681     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000167739.56948.a9     Document Type: Review

References (55)

1. Rindi G, Villanacci V, Ubiali A. Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors. Digestion 2000; 62(Suppl 1):19-26.
2. Lollgen RM, Hessman O, Szabo E, et al. Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int J Cancer 2001; 92: 812-815.
3. Grotzinger C. Tumour biology of gastroenteropancreatic neuroendocrine tumours. Neuroendocrinology 2004; 80(Suppl 1):8-11.
4. Bartsch D, Hahn SA, Danichevski KD, et al. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene 1999; 18:2367-2371.
5. Muscarella P, Melvin WS, Fisher WE, et al. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Res 1998; 58: 237-240.
6. Jensen RT. Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment. Curr Opin Oncol 2000; 12:368-377.
7. Agarwal SK, Guru SC, Heppner C, et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999; 96:143-152.
8. Calender A. Molecular genetics of neuroendocrine tumors. Digestion 2000; 62(Suppl 1):3-18.
9. Zylicz M, King FW, Wawrzynow A. Hsp70 interactions with the p53 tumour suppressor protein. EMBO J 2001; 20:4634-4638.
10. Malhotra V, Wong HR. Interactions between the heat shock response and the nuclear factor-kappaB signaling pathway. Crit Care Med 2002; 30: S89-S95.
11. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002; 295:1852-1858.
12. Zierhut B, Mechtler K, Gartner W, et al. Heat shock protein 70 (Hsp70) subtype expression in neuroendocrine tissue and identification of a neuroendocrine tumour-sipecific Hsp70 truncation. Endocr Relat Cancer 2004; 11: 377-389.
13. Barbareschi W, Roldo C, Zamboni G, et al. CDX-2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors. Am J Surg Pathol 2004; 28:1169-1176.
14. Matsuki Y, Tanimoto A, Hamada T, Sasaguri Y. Histidine decarboxylase expression as a new sensitive and specific marker for small cell lung carcinoma. Mod Pathol 2003; 16:72-78.
15. Tanimoto A, Matsuki Y, Tomita T, et al. Histidine decarboxylase expression in pancreatic endocrine cells and related tumors. Pathol Int 2004; 54: 408-412.
16. Hansel DE, Rahman A, House M, et al. Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clin Cancer Res 2004; 10:6152-6158.
17. Vortmeyer AO, Huang S, Lubensky I, Zhuang Z. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab 2004; 89:1934-1938. The origin of pancreatic islet cell tumors has been discussed over the past few years. Some authors have suggested that they develop from islet stem cells, whereas others develop from stem cells in the pancreatic tract. This paper clearly indicates that at least in MEN1, with endocrine pancreatic tumors, the tumors seem to develop from pluripotent cells within the exocrine pancreas with genetic aberrations in the MEN1 gene.
18. Hallen A. Fibrosis in the carcinoid syndrome. Lancet 1964; 15:746-747.
19. Morin LJ, Zuerner RT. Retroperitoneal fibrosis and carcinoid tumor. JAMA 1971; 216:1647-1648.
20. Moller JE, Cornolly HM, Rubin J, et al. Factors associated with progression of carcinoid heart disease. N Engl J Med 2003; 348:1005-1015.
21. Lee SL, Wang WW, Lanzillo JJ, Fanburg BL. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 1994; 266:L46-L52.
22. Waltenberger J, Lundin L, Oberg K, et al. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol 1993; 142:71-78.
23. Chaudhry A, Oberg K, Gobl A, et al. Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. Anticancer Res 1994; 14:2085-2091.
24. Zhang PJ, Furth EE, Cai X, et al. The role of beta-catenin, TGF beta 3, NGF2, FGF2, IGFR2, and BMP4 in the pathogenesis of mesenteric sclerosis and angiopathy in midgut carcinoids. Hum Pathol 2004; 35:670-674.
25. Modlin IM, Sihapiro MD, Kidd M. Carcinoid tumors and fibrosis: an association with no explanation. Am J Gastroenterol 2004; 99:2466-2478. Fibrosis and cardiac heart disease are important components of intestinal carcinoid disease and are of considerable clinical concern as both of these conditions reflect a connective tissue disorder whose etiology, biology, and therapy are unknown. This paper summarizes the current knowledge in this area and also discusses a new factor, CTGF, that is cosecreted with TGF-β1 and expressed in ileal carcinoid tumors and also is detected in the serum of patients with midgut carcinoids.
26. Stridsberg M, Oberg K, Li Q, et al. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995; 144:49-59.
27. Nobels FR, Kwekkeboom DJ, Bouillon R, Lamberts SW. Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest 1998; 28:431-440.
28. Panzuto F, Severi C, Cannizzaro R, et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest 2004; 27:6-11.
29. Kolby L, Bernhardt P, Sward C, et al. Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept 2004; 120:269-273.
30. Stridsberg M, Eriksson B, Oberg K, Janson ET. A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A. Regul Pept 2004; 117:219-227.
31. Srivastava A, Padilla O, Fischer-Colbrie R, et al. Neuroendocrine secretory protein-55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids. Am J Surg Pathol 2004; 28:1371-1378. Of new members of the chromogranin family, neuroendocrine secretorial protein-55 (NESP-55) has been studied in different NETs. In contrast to chromogranin A, which is expressed in all different types of NETs, NESP-55 seems to be restricted to endocrine pancreatic tumors and pheochromocytomas. It is not expressed in gastrointestinal or pulmonary carcinoids.
32. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660.
33. Srivastava A, Kamath A, Barry SA, Dayal Y. Ghrelin expression in hyperplastic and neoplastic proliferations of the enterochromaffin-like (ECL) cells. Endocr Pathol 2004; 15:47-54.
34. Rindi G, Necchi V, Savio A, et al. Characterisation of gastric ghrelin cells in man and other mammals: studies in adult and fetal tissues. Histochem Cell Biol 2002; 117:511-519.
35. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002; 87:2988.
36. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273:974-977.
37. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86:5992.
38. Broglio F, Koetsveld Pv P, Benso A, et al. Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. J Clin Endocrinol Metab 2002; 87:4829-4832.
39. Papotti M, Cassoni P, Volante M, et al. Ghrelin-producing endocrine tumors of the stomach and intestine. J Clin Endocrinol Metab 2001; 86:5052-5059.
40. Tsolakis AV, Portela-Gomes GM, Stridsberg M, et al. Malignant gastric ghrelinoma with hyperghrelinemia. J Clin Endocrinol Metab 2004; 89:3739-3744. This paper reports on a patient with malignant gastric carcinoid in whom tumor tissue biopsies showed immunoreactivity for ghrelin and grossly elevated circulating levels of total ghrelin 2.100 μg/L (ref. <5 μg/L) and active ghrelin 28 μg/L (ref. <0.1 μg/L) were found at presentation. The patient presented several clinical symptoms and signs, such as obesitas, diabetes, hypothyroidism, and diarrhea, but none of these symptoms could be directly correlated to the extremely high circulating ghrelin levels.
41. Scott N, Millward E, Cartwright EJ, et al. Gastrin releasing peptide and gastrin releasing peptide receptor expression in gastrointestinal carcinoid tumours. J Clin Pathol 2004; 57:189-192.
42. 111In, and 90Y-DOTA-octreotide.
43. Bombardieri E, Seregni E, Villano C, et al. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging 2004; 48:150-163.
44. 11C-5-HTP is more sensitive than octreoscan and CT scanning for detection of small GEP NETs, and it is also of value for monitoring of therapy.
45. Gabriel M, Decristoforo C, Maina T, et al. 99mTc-N4-[Tyr3]octreotate versus 99mTc-EDDA/HYNIC-[Tyr3]octreotide: an intrapatient comparison of two novel technetium-99m labeled tracers for somatostatin receptor scintigraphy. Cancer Biother Radiopharm 2004; 19:73-79.
46. de Herder WW, Krenning EP, Van Eijck CH, Lamberts SW. Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas. Endocr Relat Cancer 2004; 11:19-34.
47. Shah MH, Young D, Kindler HL, et al. Phase II study of the proteasome inhibitor bortezomib (PS-341 ) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004; 10:6111-6118.
48. Oberg K. Interferons in the management of neuroendocrine tumors and their possible mechanism of action. Yale J Biol Med 1992; 65:519-529; discussion 531-516.
49. Rosewicz S, Detjen K, Scholz A, von Marschall Z. Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 2004; 80(Suppl 1):85-93.
50. Stuart K, Levy DE, Anderson T, et al. Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs 2004; 22:75-81.
51. Welin SV, Janson ET, Sundin A, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 2004; 151:107-112.
52. Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004; 80(Suppl 1):47-50.
53. Kulke MH, Kim H, Clark JW, et al. A phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 2004; 101:934-939.
54. Kulke MH, Kim H, Stuart K, et al. A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest 2004; 22:353-359.
55. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25:458-511. This extensive review of diagnosis and medical management of advanced NETs discusses different types of NETs, including GEP NETs. It includes 620 references and covers the past and present views on diagnosis and management of these tumors.